Lista de obras - Charles M. Beasley - Dominio Público Uruguay

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse ⬇️

artículo científico publicado el 1 de diciembre de 2003

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia

artículo científico publicado en 1998

A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil

artículo científico publicado en 2004

Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis

artículo científico publicado en 2000

All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis

scientific article published on 01 June 2007

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol ⬇️

artículo científico publicado el 1 de septiembre de 1997

Blood pressure changes during short-term fluoxetine treatment.

artículo científico publicado en 1999

Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.

artículo científico publicado en 2002

Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings

artículo científico publicado en 2008

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders

artículo científico publicado en 1997

Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis

artículo científico publicado en 2006

Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers.

artículo científico publicado en 2013

Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.

artículo científico publicado en 2003

Efficacy and safety of fluoxetine in treating bipolar II major depressive episode.

artículo científico publicado en 1998

Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial

artículo científico publicado en 2005

Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder

artículo científico publicado en 2007

Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials

artículo científico publicado en 2007

Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment

artículo científico publicado en 2002

Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study ⬇️

artículo científico publicado el 1 de julio de 1997

Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy.

artículo científico publicado en 2001

Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression

artículo científico publicado en 1991

Fluoxetine efficacy in menopausal women with and without estrogen replacement

artículo científico publicado en 1999

Fluoxetine in Depressed Patients on Dialysis ⬇️

artículo científico publicado el 1 de enero de 1997

Fluoxetine in medically stable, depressed geriatric patients: effects on weight

artículo científico publicado en 1997

Fluoxetine: a review of receptor and functional effects and their clinical implications.

artículo científico publicado en 1992

Fluoxetine: no association with suicidality in obsessive-compulsive disorder

scientific article published on 01 January 1992

Hematologic reference ranges in a population of patients with schizophrenia

artículo científico publicado en 2000

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.

artículo científico publicado en 2002

Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?

artículo científico publicado en 2006

Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients

artículo científico publicado en 1997

Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial

artículo científico publicado en 2001

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial

artículo científico publicado en 1999

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial

artículo científico publicado en 1997

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

scientific article published on 01 February 1996

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial

artículo científico publicado en 1998

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

artículo científico publicado en 1996

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

artículo científico publicado en 1999

Optimal Length of Continuation Therapy in Depression: A Prospective Assessment During Long-Term Fluoxetine Treatment ⬇️

artículo científico publicado el 1 de septiembre de 1998

Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia ⬇️

artículo científico publicado el 1 de diciembre de 1997

Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report

artículo científico publicado en 2010

Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement

artículo científico publicado en 2010

Systematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditions

artículo científico publicado en 2011

Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones.

artículo científico publicado en 2003

Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial

artículo científico publicado en 2005

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations ⬇️

artículo científico publicado el 25 de julio de 1997

The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval

artículo científico publicado en 2005

Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes.

artículo científico publicado en 2007

Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo

artículo científico publicado en 1998

Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials

artículo científico publicado en 2010

Lista de obras de Charles M. Beasley

A Double-Blind, Randomized, Placebo-Controlled Trial of Olanzapine in the Prevention of Psychotic Relapse ⬇️

A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia

A multicenter, randomized, double-blind, crossover study to evaluate patient preference between tadalafil and sildenafil

Adverse events and treatment discontinuations in clinical trials of fluoxetine in major depressive disorder: an updated meta-analysis

All-cause treatment discontinuation in schizophrenia during treatment with olanzapine relative to other antipsychotics: an integrated analysis

Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol ⬇️

Blood pressure changes during short-term fluoxetine treatment.

Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia.

Design and analysis considerations for thorough QT studies employing conventional (10 s, 12-lead) ECG recordings

Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders

Effects of antipsychotic drugs on I(to), I (Na), I (sus), I (K1), and hERG: QT prolongation, structure activity relationship, and network analysis

Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers.

Effects of intramuscular olanzapine vs. haloperidol and placebo on QTc intervals in acutely agitated patients.

Efficacy and safety of fluoxetine in treating bipolar II major depressive episode.

Efficacy and safety of oral tadalafil in the treatment of men in Canada with erectile dysfunction: a randomized, double-blind, parallel, placebo-controlled clinical trial

Evaluating suicide-related adverse events in clinical trials of fluoxetine treatment in adults for indications other than major depressive disorder

Fluoxetine and adult suicidality revisited: an updated meta-analysis using expanded data sources from placebo-controlled trials

Fluoxetine and norfluoxetine plasma concentrations during relapse-prevention treatment

Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study ⬇️

Fluoxetine and norfluoxetine plasma levels after discontinuing fluoxetine therapy.

Fluoxetine and suicide: a meta-analysis of controlled trials of treatment for depression

Fluoxetine efficacy in menopausal women with and without estrogen replacement

Fluoxetine in Depressed Patients on Dialysis ⬇️

Fluoxetine in medically stable, depressed geriatric patients: effects on weight

Fluoxetine: a review of receptor and functional effects and their clinical implications.

Fluoxetine: no association with suicidality in obsessive-compulsive disorder

Hematologic reference ranges in a population of patients with schizophrenia

Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.

Is quality of life among minimally symptomatic patients with schizophrenia better following withdrawal or continuation of antipsychotic treatment?

Olanzapine plasma concentrations and clinical response in acutely ill schizophrenic patients

Olanzapine plasma concentrations and clinical response: acute phase results of the North American Olanzapine Trial

Olanzapine versus haloperidol in the treatment of schizophrenia and other psychotic disorders: quality of life and clinical outcomes of a randomized clinical trial

Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

Olanzapine. Pharmacokinetic and pharmacodynamic profile.

Optimal Length of Continuation Therapy in Depression: A Prospective Assessment During Long-Term Fluoxetine Treatment ⬇️

Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia ⬇️

Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report

Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement

Systematic decrements in QTc between the first and second day of contiguous daily ECG recordings under controlled conditions

Tadalafil has no detrimental effect on human spermatogenesis or reproductive hormones.

Tadalafil improved erectile function at twenty-four and thirty-six hours after dosing in men with erectile dysfunction: US trial

The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations ⬇️

The combined use of ibutilide as an active control with intensive electrocardiographic sampling and signal averaging as a sensitive method to assess the effects of tadalafil on the human QT interval

Treatment-associated suicidal ideation and adverse effects in an open, multicenter trial of fluoxetine for major depressive episodes.

Use of pattern analysis to predict differential relapse of remitted patients with major depression during 1 year of treatment with fluoxetine or placebo

Weight changes over time in adults treated with the oral or depot formulations of olanzapine: a pooled analysis of 86 clinical trials